BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53:354-361. [PMID: 29138921 DOI: 10.1007/s00535-017-1407-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 15.3] [Reference Citation Analysis]
Number Citing Articles
1 Sugimoto M, Yasuda H, Andoh A. Nutrition status and Helicobacter pylori infection in patients receiving hemodialysis. World J Gastroenterol 2018; 24(15): 1591-1600 [PMID: 29686466 DOI: 10.3748/wjg.v24.i15.1591] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Huang D, Yang Y, Zhang S, Su Z, Peng T, Wang X, Zhao Y, Li S. Regulatory T-cell density and cytotoxic T lymphocyte density are associated with complete response to neoadjuvant paclitaxel and carboplatin chemoradiotherapy in gastric cancer. Exp Ther Med 2018;16:3813-20. [PMID: 30344657 DOI: 10.3892/etm.2018.6684] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Kakiuchi T, Matsuo M, Endo H, Nakayama A, Sato K, Takamori A, Sasaki K, Takasaki M, Hara M, Sakata Y, Okuda M, Kikuchi S, Eguchi Y, Takahashi H, Anzai K, Fujimoto K. A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture: a preliminary report. J Gastroenterol 2019;54:699-707. [DOI: 10.1007/s00535-019-01559-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
4 Sgambato D, Visciola G, Ferrante E, Miranda A, Romano L, Tuccillo C, Manguso F, Romano M. Prevalence of Helicobacter pylori infection in sexual partners of H. pylori-infected subjects: Role of gastroesophageal reflux. United European Gastroenterol J. 2018;6:1470-1476. [PMID: 30574317 DOI: 10.1177/2050640618800628] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
5 Kakiuchi T, Matsuo M, Endo H, Sakata Y, Esaki M, Noda T, Imamura I, Hashiguchi K, Ogata S, Fujioka Y, Hanada K, Fukuda K, Yoshimura M, Kajiwara T, Yamamoto K, Yamaguchi D, Kawakubo H, Akashi T, Sumino M, Matsunaga K, Muro E, Kuwahara A, Taniguchi K, Fukuyama K, Watanabe A, Takamori A, Okuda M, Yamanouchi K, Fujimoto K. Gastrointestinal adverse reactions reduce the success rate of Helicobacter pylori eradication therapy: A multicenter prospective cohort study. Helicobacter 2021;26:e12776. [PMID: 33368891 DOI: 10.1111/hel.12776] [Reference Citation Analysis]
6 Lim H, Bang CS, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, Lee JJ, Baik GH, Kim DJ. Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial. Medicine (Baltimore) 2018;97:e13245. [PMID: 30431605 DOI: 10.1097/MD.0000000000013245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
7 Kakiuchi T, Takamori A, Matsuo M. High Prevalence of Helicobacter pylori Infection in Special Needs Schools in Japan. Front Pediatr 2021;9:697200. [PMID: 34307259 DOI: 10.3389/fped.2021.697200] [Reference Citation Analysis]
8 Koldby KM, Mortensen MB, Detlefsen S, Pfeiffer P, Thomassen M, Kruse TA. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients. J Gastroenterol 2019;54:108-21. [PMID: 30242476 DOI: 10.1007/s00535-018-1508-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Paz MFCJ, de Alencar MVOB, de Lima RMP, Sobral ALP, do Nascimento GTM, Dos Reis CA, Coêlho MDPSS, do Nascimento MLLB, Gomes Júnior AL, Machado KDC, de Menezes APM, de Lima RMT, de Oliveira Filho JWG, Dias ACS, Dos Reis AC, da Mata AMOF, Machado SA, Sousa CDC, da Silva FCC, Islam MT, de Castro E Sousa JM, Melo Cavalcante AAC. Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer. Oxid Med Cell Longev 2020;2020:3457890. [PMID: 32308801 DOI: 10.1155/2020/3457890] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lee JY, Kim N, Nam RH, In Choi S, Lee JW, Lee DH. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. Helicobacter. 2019;24:e12660. [PMID: 31507036 DOI: 10.1111/hel.12660] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
11 Huh KY, Chung H, Kim YK, Lee S, Bhatia S, Takanami Y, Nakaya R, Yu KS. Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication. Br J Clin Pharmacol 2021. [PMID: 34080718 DOI: 10.1111/bcp.14934] [Reference Citation Analysis]
12 Pih GY, Choi KD, Gong EJ, Na HK, Ahn JY, Lee JH, Jung KW, Kim DH, Song HJ, Lee GH, Jung HY. Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection. Helicobacter 2021;26:e12759. [PMID: 33113240 DOI: 10.1111/hel.12759] [Reference Citation Analysis]
13 Wojtyś MI, Jaźwiec R, Kazazić S, Leščić Ašler I, Knežević P, Aleksić Sabo V, Luić M, Jagusztyn-Krynicka EK, Bzowska A. A comprehensive method for determining cellular uptake of purine nucleoside phosphorylase and adenylosuccinate synthetase inhibitors by H. pylori. Appl Microbiol Biotechnol 2021;105:7949-67. [PMID: 34562116 DOI: 10.1007/s00253-021-11510-9] [Reference Citation Analysis]
14 Lin TF, Hsu PI. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J Gastroenterol 2018; 24(40): 4548-4553 [PMID: 30386104 DOI: 10.3748/wjg.v24.i40.4548] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
15 Zhang S, Wang X, Wise MJ, He Y, Chen H, Liu A, Huang H, Young S, Tay CY, Marshall BJ, Li X, Chua EG. Mutations of Helicobacter pylori RdxA are mainly related to the phylogenetic origin of the strain and not to metronidazole resistance. J Antimicrob Chemother 2020;75:3152-5. [PMID: 32676634 DOI: 10.1093/jac/dkaa302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kubosawa Y, Mori H, Kinoshita S, Nakazato Y, Fujimoto A, Kikuchi M, Nishizawa T, Suzuki M, Suzuki H. Changes of gastric ulcer bleeding in the metropolitan area of Japan. World J Gastroenterol 2019; 25(42): 6342-6353 [PMID: 31754294 DOI: 10.3748/wjg.v25.i42.6342] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, Watari J, Miwa H. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018;23:e12495. [PMID: 29873436 DOI: 10.1111/hel.12495] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
18 Fujimoto S, Tsuruoka N, Esaki M, Takamori A, Sakata Y, Shimoda R, Akutagawa T, Node K, Anzai K, Sugisaki N, Iwakiri R, Takagi K, Yamanouchi K, Fujimoto K. Decline incidence in upper gastrointestinal bleeding in several recent years: data of the Japan claims database of 13 million accumulated patients. J Clin Biochem Nutr 2021;68:95-100. [PMID: 33536718 DOI: 10.3164/jcbn.20-153] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Xie Y, Song C, Cheng H, Xu C, Zhang Z, Wang J, Huo L, Du Q, Xu J, Chen Y, Zhang X, Zhang G, Yang G, Zuo X, Guo T, Lu Y, Wang F, Wang X, Zhuang K, Chen S, Liu W, Lu N; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Long-term follow-up of Helicobacter pylori reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study. Emerg Microbes Infect 2020;9:548-57. [PMID: 32160805 DOI: 10.1080/22221751.2020.1737579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
20 Park CG, Kim S, Jeon HS, Han S. Validation of loop-mediated isothermal amplification to detect Helicobacter pylori and 23S rRNA mutations: A prospective, observational clinical cohort study. J Clin Lab Anal 2021;35:e23563. [PMID: 32893424 DOI: 10.1002/jcla.23563] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Shichijo S, Endo Y, Aoyama K, Takeuchi Y, Ozawa T, Takiyama H, Matsuo K, Fujishiro M, Ishihara S, Ishihara R, Tada T. Application of convolutional neural networks for evaluating Helicobacter pylori infection status on the basis of endoscopic images. Scand J Gastroenterol. 2019;54:158-163. [PMID: 30879352 DOI: 10.1080/00365521.2019.1577486] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
22 Choi JH, Yang YJ, Bang CS, Lee JJ, Baik GH. Current Status of the Third-Line Helicobacter pylori Eradication. Gastroenterol Res Pract 2018;2018:6523653. [PMID: 29853863 DOI: 10.1155/2018/6523653] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
23 de Assumpção PP, Araújo TMT, de Assumpção PB, Barra WF, Khayat AS, Assumpção CB, Ishak G, Nunes DN, Dias-neto E, Coelho LGV. Suicide journey of H. pylori through gastric carcinogenesis: the role of non-H. pylori microbiome and potential consequences for clinical practice. Eur J Clin Microbiol Infect Dis 2019;38:1591-7. [DOI: 10.1007/s10096-019-03564-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
24 Zhao H, Yan P, Zhang N, Feng L, Chu X, Cui G, Qin Y, Yang C, Wang S, Yang K. The recurrence rate of Helicobacter pylori in recent 10 years: A systematic review and meta-analysis. Helicobacter 2021;26:e12852. [PMID: 34510644 DOI: 10.1111/hel.12852] [Reference Citation Analysis]
25 Polyzos SA, Kountouras J, Mantzoros CS. Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction? Metabolism 2019;96:iii-v. [DOI: 10.1016/j.metabol.2019.05.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
26 Ng HK, Goh KL, Chuah KH, Thalha AM, Kee BP, Por LY, Chua KH, Puah SM. Sequencing-based detection of 23S rRNA domain V mutations in treatment-naïve Helicobacter pylori patients from Malaysia. J Glob Antimicrob Resist 2020;23:345-8. [PMID: 33137535 DOI: 10.1016/j.jgar.2020.10.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Abadi ATB, Ierardi E. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon? Front Pharmacol. 2019;10:316. [PMID: 31024299 DOI: 10.3389/fphar.2019.00316] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
28 Nam K, Shin JE, Kim SE, Baik GH, Choi SH, Lee JY, Park KS, Joo Y, Myung D, Kim HJ, Song HJ, Choi SC, Kim HJ, Kim HY, Kim N. Prevalence and risk factors for upper gastrointestinal diseases in health check-up subjects: a nationwide multicenter study in Korea. Scandinavian Journal of Gastroenterology 2018;53:910-6. [DOI: 10.1080/00365521.2018.1487992] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
29 Suzuki H, Mori H. Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next? United European Gastroenterol J 2021;9:7-8. [PMID: 33210981 DOI: 10.1177/2050640620975357] [Reference Citation Analysis]
30 Kakiuchi T, Okuda M, Hashiguchi K, Imamura I, Nakayama A, Matsuo M. Evaluation of a Novel Stool Antigen Rapid Test Kit for Detection of Helicobacter pylori Infection. J Clin Microbiol 2019;57:e01825-18. [PMID: 30567746 DOI: 10.1128/JCM.01825-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Kawahara Y, Kodama M, Mizukami K, Saito T, Hirashita Y, Sonoda A, Fukuda K, Matsunari O, Okamoto K, Ogawa R, Okimoto T, Murakami K. Endoscopic gastric mucosal atrophy as a predictor of colorectal polyps: a large scale case-control study. J Clin Biochem Nutr 2019;65:153-9. [PMID: 31592060 DOI: 10.3164/jcbn.19-47] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Hua H, Zhang H, Kong Q, Wang J, Jiang Y. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med Res Rev 2019;39:114-45. [PMID: 29855050 DOI: 10.1002/med.21514] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 13.7] [Reference Citation Analysis]
33 Mori H, Suzuki H. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. J Neurogastroenterol Motil. 2019;25:6-14. [PMID: 30504527 DOI: 10.5056/jnm18139] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
34 Xie W, Zhao W, Zou Z, Kong L, Yang L. Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL / 6 mice. Helicobacter 2021;26. [DOI: 10.1111/hel.12807] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Murata M, Sugimoto M, Otsuka T, Nishida A, Inatomi O, Bamba S, Andoh A. Successful Helicobacter pylori eradication therapy improves symptoms of chronic constipation. Helicobacter 2018;23. [DOI: 10.1111/hel.12543] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Kountouras J, Doulberis M, Papaefthymiou A, Polyzos SA, Vardaka E, Tzivras D, Dardiotis E, Deretzi G, Giartza‐taxidou E, Grigoriadis S, Katsinelos P. A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection. Ann N Y Acad Sci 2019;1452:12-7. [DOI: 10.1111/nyas.14168] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
37 Li RJ, Dai YY, Qin C, Li XH, Qin YC, Pan Y, Huang YY, Huang ZS, Huang YQ. Treatment strategies and preventive methods for drug-resistant Helicobacter pylori infection. World J Meta-Anal 2020; 8(2): 98-108 [DOI: 10.13105/wjma.v8.i2.98] [Reference Citation Analysis]
38 Xu Y, Tan Y, Wang Y, Gao J, Wu D, Xu X. A Gratifying Step forward for the Application of Artificial Intelligence in the Field of Endoscopy: A Narrative Review. Surg Laparosc Endosc Percutan Tech 2020;31:254-63. [PMID: 33122593 DOI: 10.1097/SLE.0000000000000881] [Reference Citation Analysis]
39 Kakiuchi T, Hashiguchi K, Imamura I, Nakayama A, Takamori A, Okuda M, Matsuo M. Assessment of a novel method to detect clarithromycin-resistant Helicobacter pylori using a stool antigen test reagent. BMC Gastroenterol 2020;20:397. [PMID: 33228552 DOI: 10.1186/s12876-020-01549-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Yu J, Yang P, Qin X, Li C, Lv Y, Wang X. Impact of smoking on the eradication of Helicobacter pylori. Helicobacter 2021;:e12860. [PMID: 34708484 DOI: 10.1111/hel.12860] [Reference Citation Analysis]
41 Bubić A, Mrnjavac N, Stuparević I, Łyczek M, Wielgus-Kutrowska B, Bzowska A, Luić M, Leščić Ašler I. In the quest for new targets for pathogen eradication: the adenylosuccinate synthetase from the bacterium Helicobacter pylori. J Enzyme Inhib Med Chem 2018;33:1405-14. [PMID: 30191734 DOI: 10.1080/14756366.2018.1506773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Kwon YJ, Kim N, Baek SM, Lee HS, Lee J, Hwang YJ, Yoon H, Shin CM, Park YS, Kim J, Lee DH. The prevalence of histologic atrophy and intestinal metaplasia in the corpus has decreased over 15 years in females in the Korean population. Helicobacter 2019;24:e12579. [DOI: 10.1111/hel.12579] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
43 Chey WD. Helicobacter pylori: When We Should Treat…. Am J Gastroenterol 2019;114:1829-32. [DOI: 10.14309/ajg.0000000000000425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Haddadi MH, Negahdari B, Asadolahi R, Bazargani A. Helicobacter pylori antibiotic resistance and correlation with cagA motifs and homB gene. Postgrad Med 2020;132:512-20. [PMID: 32281451 DOI: 10.1080/00325481.2020.1753406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
45 Mori H, Suzuki H. Update on quinolone-containing rescue therapies for Helicobacter pylori infection. World J Gastroenterol 2020; 26(15): 1733-1744 [PMID: 32351290 DOI: 10.3748/wjg.v26.i15.1733] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
46 Liatsos C, Papaefthymiou A, Kyriakos N, Giakoumis M, Kountouras J, Galanopoulos M, Apostolopoulos P, Georgopoulos SD, Mavrogiannis C, Exadaktylos AK, Srivastava DS, Rokkas T, Doulberis M. Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care? Medicina (Kaunas) 2020;56:E133. [PMID: 32197498 DOI: 10.3390/medicina56030133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
47 Al-Eitan LN, Almomani FA, Al-Khatib SM. Association of CYP2C19, TNF-α, NOD1, NOD2, and PPARγ polymorphisms with peptic ulcer disease enhanced by Helicobacter pylori infection. Saudi Med J 2021;42:21-9. [PMID: 33399167 DOI: 10.15537/smj.2021.1.25654] [Reference Citation Analysis]
48 Choi CK, Kweon SS, Cho SH, Kim HY, Shin MH. Association between ALDH2 Polymorphism and Gastric Cancer Risk in a Korean Population. J Korean Med Sci 2020;35:e148. [PMID: 32356421 DOI: 10.3346/jkms.2020.35.e148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Ishioka K, Masaoka H, Ito H, Oze I, Ito S, Tajika M, Shimizu Y, Niwa Y, Nakamura S, Matsuo K. Association between ALDH2 and ADH1B polymorphisms, alcohol drinking and gastric cancer: a replication and mediation analysis. Gastric Cancer 2018;21:936-45. [PMID: 29616362 DOI: 10.1007/s10120-018-0823-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
50 Toporcov TN, Wünsch Filho V. Epidemiological science and cancer control. Clinics (Sao Paulo) 2018;73:e627s. [PMID: 30281702 DOI: 10.6061/clinics/2018/e627s] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
51 Ansari S, Akada J, Matsuo Y, Shiota S, Kudo Y, Okimoto T, Murakami K, Yamaoka Y. Epitope peptides of Helicobacter pylori CagA antibodies from sera by whole-peptide mapping. J Gastroenterol 2019;54:1039-51. [PMID: 31049715 DOI: 10.1007/s00535-019-01584-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Yan H, Xiao F, Zou J, Qiu C, Sun W, Gu M, Zhang L. NR4A1-induced increase in the sensitivity of a human gastric cancer line to TNFα-mediated apoptosis is associated with the inhibition of JNK/Parkin-dependent mitophagy. Int J Oncol 2018;52:367-78. [PMID: 29207128 DOI: 10.3892/ijo.2017.4216] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
53 Rizvanov AA, Haertlé T, Bogomolnaya L, Talebi Bezmin Abadi A. Helicobacter pylori and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines. Front Microbiol 2019;10:1796. [PMID: 31456763 DOI: 10.3389/fmicb.2019.01796] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
54 Okuda M, Lin Y, Wang C, Kakiuchi T, Kikuchi S. Metronidazole for Helicobacter pylori eradication therapy among children and adolescents in Japan: Overcoming controversies and concerns. Helicobacter. 2019;24:e12575. [PMID: 30873719 DOI: 10.1111/hel.12575] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
55 Okushin K, Tsutsumi T, Ikeuchi K, Kado A, Enooku K, Fujinaga H, Moriya K, Yotsuyanagi H, Koike K. Helicobacter pylori infection and liver diseases: Epidemiology and insights into pathogenesis. World J Gastroenterol 2018; 24(32): 3617-3625 [PMID: 30166857 DOI: 10.3748/wjg.v24.i32.3617] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
56 Al-Hussaini AA, Al Jurayyan AN, Bashir SM, Alshahrani D. Where are we today with Helicobacter pylori infection among healthy children in Saudi Arabia? Saudi J Gastroenterol. 2019;25:309-318. [PMID: 31006713 DOI: 10.4103/sjg.sjg_531_18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
57 Miftahussurur M, Pratama Putra B, Yamaoka Y. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals (Basel) 2020;13:E276. [PMID: 32998241 DOI: 10.3390/ph13100276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Nishizawa T, Munkjargal M, Ebinuma H, Toyoshima O, Suzuki H. Sitafloxacin for Third-Line Helicobacter pylori Eradication: A Systematic Review. J Clin Med 2021;10:2722. [PMID: 34202993 DOI: 10.3390/jcm10122722] [Reference Citation Analysis]
59 Mori H, Suzuki H, Omata F, Masaoka T, Asaoka D, Kawakami K, Mizuno S, Kurihara N, Nagahara A, Sakaki N, Ito M, Kawamura Y, Suzuki M, Shimada Y, Sasaki H, Matsuhisa T, Torii A, Nishizawa T, Mine T, Ohkusa T, Kawai T, Tokunaga K, Takahashi S. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients. Therap Adv Gastroenterol. 2019;12:1756284819858511. [PMID: 31320930 DOI: 10.1177/1756284819858511] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
60 Salehi N, Attaran B, Eskini N, Esmaeili M, Sharifirad A, Sadeghi M, Mohammadi M. New insights into resistance of Helicobacter pylori against third‐ and fourth‐generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations. Helicobacter 2019;24. [DOI: 10.1111/hel.12628] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Schramm VL. Enzymatic Transition States and Drug Design. Chem Rev 2018;118:11194-258. [PMID: 30335982 DOI: 10.1021/acs.chemrev.8b00369] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]